Muhammad Ishfaq

Muhammad Ishfaq

Auto-generated profile, based on publicly available information

Muhammad Ishfaq

Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MTMohammad Tariq
Mohammad Tariq
AIAkihiro Ito
Akihiro Ito
MIMuhammad Ishfaq
Muhammad Ishfaq
EBElliot Bradshaw
Elliot Bradshaw
MYMinoru Yoshida
Minoru Yoshida

1 January 2017 in Microbial Pathogenesis
Verified
Journal Article
Closed access
TKTaj Ali Khan
Taj Ali Khan
HMHumaira Mazhar
Humaira Mazhar
MNMehboob Nawaz
Mehboob Nawaz
KKKalsoom Kalsoom
Kalsoom Kalsoom
MIMuhammad Ishfaq
Muhammad Ishfaq
AIAsif Iqbal
Asif Iqbal

1 August 2017 in Microbial Pathogenesis
Verified
Journal Article
Closed access
TKTaj Ali Khan
Taj Ali Khan
AIAsif Iqbal
Asif Iqbal
HRHazir Rahman
Hazir Rahman
OMOtavio Marques
Otavio Marques
MIMuhammad Ishfaq
Muhammad Ishfaq
NMNoor Muhammad
Noor Muhammad

17 September 2025 in Journal of Infection and Public Health
Verified
Journal Article
Open access
AZAsad Zia
Asad Zia
AIArshad Islam
Arshad Islam
SASyeda Aiman
Syeda Aiman
SKSalman Khan
Salman Khan
KKKhizar Abdullah Khan
Khizar Abdullah Khan
YYYasar Mehmood Yousafzai
Yasar Mehmood Yousafzai
Crimean-Congo hemorrhagic fever virus (CCHFV) poses a significant public health threat, particularly in Khyber Pakhtunkhwa, Pakistan, where its prevalence and epidemiological distribution remain poorly documented. This study aimed to investigate the epidemiology, prevalence, and transmission dynamics of the 2023 CCHFV outbreak in Khyber Pakhtunkhwa during the Eid-ul-Adha season. From April to July 2023, 109 suspected cases were enrolled. Laboratory confirmation was performed using real-time reverse transcription polymerase chain reaction (RT-PCR). Demographic, clinical, and epidemiological data were analyzed to identify high-risk groups and outbreak dynamics. Out of the suspected cases, 15 (13.76 %) were confirmed CCHFV positive, with males comprising 80 % of cases (n = 12). The highest prevalence (33.33 %) was recorded in Peshawar district, and 53 % of cases had a history of animal exposure. A significant spike (5 cases) occurred in the 29th epidemiological week, following Eid-ul-Adha. Clinical symptoms included fever, body aches, confusion, and bleeding episodes. The case fatality rate (CFR) was 26.67 % (male-specific CFR: 33.33 %), while all female patients recovered. These findings underscore the critical public health concern posed by CCHFV in Khyber Pakhtunkhwa. The heightened risk associated with Eid-ul-Adha, coupled with age and gender demographics, necessitates targeted awareness initiatives, preventive strategies, and strengthened surveillance during peak risk periods to mitigate transmission and prevent future outbreaks. However, it's important to acknowledge the study's limitations, such as the relatively small sample size, potential selection bias, and the absence of a control group. Future research with larger sample sizes and more comprehensive data collection is essential to gain a deeper understanding of the epidemiology and transmission dynamics of CCHFV in this region.

12 November 2025 in Blood Advances
Verified
Journal Article
Open access
MPMark Perfetto
Mark Perfetto
ADAidan Danoff
Aidan Danoff
MIMuhammad Ishfaq
Muhammad Ishfaq
HMHeidi Monroe
Heidi Monroe
AMAiden Mohideen
Aiden Mohideen
YYYvette Y. Yien
Yvette Y. Yien
Iron metabolism drives key erythropoietic processes, including hemoglobinization, survival, and proliferation. Here, we developed in vivo methods to interrogate how iron regulates erythropoiesis and report that mitochondrial iron transport via mitoferrin-1 (MFRN1) is essential for erythroid cell cycle progression. mfrn1 embryos had severely decreased erythroid cell number caused by cell cycle arrest at G2/M. They had enlarged nuclei, suggesting a mitotic defect. Iron supplementation rescued the cell cycle defect, implicating mitochondrial iron deficiency as its cause. In contrast, fpn1 mutants, anemic from systemic iron deficiency, had less severe decreases in erythroid mitochondrial iron than mfrn1 mutants and no proliferative defects. Single-cell RNA sequencing and fluorescence-activated flow sorting analyses for cd41 (thrombocytic) and gata1 reporters indicated that developmental defects in mfrn1 mutants were largely erythroid restricted. This defect was specific to terminally differentiating erythroid cells. Although mfrn1 mutant erythroid cells from 1.5 days post fertilization (dpf) embryos did not experience decreased cell number, mfrn1 mutant gata1+ erythroid progenitors were severely decreased at 3 dpf, and a further decrease in globin-expressing terminally differentiating erythroid cells. Although wild-type erythroid cells mostly lost expression of the gata1 progenitor marker by 3 dpf, mfrn1 mutant erythroid cells retained gata1 expression. These data are consistent with a model in which mitochondrial iron transport facilitates development of gata1+ erythroid progenitors and is required for the completion of erythropoiesis by facilitating mitosis in the terminal cell cycles.

31 March 2026 in Blood Red Cells & Iron
Verified
Journal Article
Open access
Malini SharmaMalini Sharma
Malini Sharma
MIMuhammad Ishfaq
Muhammad Ishfaq
PMParitosh Mondal
Paritosh Mondal
AMAiden Mohideen
Aiden Mohideen
FCFabliha A. Chowdhury
Fabliha A. Chowdhury
JXJulia Z. Xu
Julia Z. Xu
Sickle cell disease (SCD) causes erythrocyte sickling and downstream sequelae, including hemolysis, iron mishandling, and subclinical renal dysfunction, thereby reducing erythropoietic drive. These effects result in chronic anemia that drives SCD-related complications. Treatment of severe anemia in SCD with frequent subcutaneous injections of erythropoiesis-stimulating agents is often poorly tolerated by patients, underscoring the need for oral treatments. Here, we provide key insights into how daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stimulates red cell production, may serve as a targeted treatment for anemia in SCD. In a mouse model of SCD, daprodustat increases red blood cell production, reduces sickling, and improves iron mobilization by suppressing hepatic hepcidin expression, thereby enhancing iron availability for erythropoiesis and ameliorating chronic anemia. In addition to these systemic, non-cell-autonomous effects on iron homeostasis, daprodustat directly induces γ-globin expression and increases the production of fetal hemoglobin-containing erythroid cells (F-cells) derived from CD34+ hematopoietic stem and progenitor cells of patients with SCD, conferring cell-autonomous therapeutic benefits. These findings demonstrate that HIF-PHIs act on multiple therapeutic targets in SCD and represent a promising oral treatment option for chronic anemia in this disease.